We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Novozymes Announces Master File for Recombinant Albumin


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Novozymes Announces Master File for Recombinant Albumin"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 
Novozymes Biopharma, part of Novozymes A/S announced that the US Food and Drug Administration Center for Biologics Evaluation and Research (FDA / CBER) has accepted a Type IV Master File for its recombinant albumin, albucult®.

The dossier which contains proprietary information on the manufacture and safety of albucult, can help support the company’s customers in applications such as drug formulation and medical devices. By providing customers with access to a single source of information filed with the FDA as part of their product applications, Novozymes can help to accelerate the regulatory process for products that use albucult.

Derived from Novozymes’ proprietary yeast expression technology, albucult can deliver quality benefits to a range of applications including drug and vaccine manufacture, device coating, sealants, IVF media and cell therapy applications.

albucult complies with the excipient monograph standard for recombinant human albumin, published in the United States Pharmacopoeia – National Formulary (USP-NF) and confers a range of advantages including sustainability of supply and improved biocompatibility. In addition, albucult ensures batch-to-batch consistency which can reduce lot testing burden for clients.

Wayne Prestwood, principal regulatory associate at Novozymes Biopharma, comments: “The company is always looking for the most effective ways of supporting our customers’ applications through regulatory processes and we are delighted to have a master file for albucult accepted by CBER. By ensuring that the information required by the FDA as part of our customers’ review processes is readily available, we can help speed up their regulatory approvals, enabling their products to be delivered to market faster.”
Advertisement